Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company AbbVie Inc.
DescriptionAntibody-drug conjugate (ADC) composed of a humanized mAb against c-Met receptor tyrosine kinase (c-MET; MET; HGFR; c-Met proto-oncogene) and monomethyl auristatin E (MMAE)
Molecular Target c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) (c-Met proto-oncogene)
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced solid tumors
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today